Novartis moved to strengthen CNS delivery by paying Sironax $125 million to take up an option on a blood-brain barrier crossing platform. The transaction gives Novartis control of technology aimed at moving large molecules into the central nervous system. The deal highlights continued pharma demand for modality-agnostic delivery platforms, particularly those that can help advance antibody and biologic programs for neurologic indications—where BBB constraints remain a central development bottleneck. In parallel, Novartis is also pairing its deal activity with operational execution signals in immunology and oncology, reflecting a broader strategy of building capabilities that extend beyond single assets. For biotech partners, the Sironax move reinforces that platform economics—upfront control plus milestones—remain attractive to big pharma when the technical risk is framed as “delivery solvable.”